Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
ForecastedResearch announcementOpportunity RFA-MH-27-110

Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks

National Institutes of Health · Department of Health and Human Services

At a glance

Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks is a forecasted federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of October 22, 2026; forecast dates can change. Total estimated funding is $2M across about 4 awards. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.242 (Mental Health Research Grants).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Mar 16, 2026Forecast posted
  2. Aug 17, 2026 (est.)Full notice expected
  3. Oct 22, 2026 (est.)Application deadlinenext date
  4. Jul 1, 2027 (est.)Est. award date
Posted
Mar 16, 2026
Est. close date
Oct 22, 2026
Est. award date
Jul 1, 2027
Award floor
Not specified
Award ceiling
Not specified
Est. total funding
$2,000,000
Implied average award
$500,000 calculated
Expected awards
4
Cost sharing
Not required
Funding instrument
Grant
Opportunity category
Discretionary
Fiscal year
FY2027

Typical awards for this program (SAM.gov listing for ALN 93.242, not this notice): FY 2023 range: $1 to $17,379,729 Average Cost: $508,267

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV and to identify mechanisms, benefits, and risks associated with their use in the CNS compartment. The primary goal is to generate evidence that informs whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. By addressing CNS-specific barriers such as blood brain barrier penetration, compartmentalized viral dynamics, and immune-mediated effects, this NOFO will support the development of strategies that contribute to sustained virologic remission across anatomical compartments and improve long-term neurologic and cognitive outcomes in people with HIV. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into the impact of HIV immunotherapies on the CNS and viral reservoirs are strongly encouraged to apply to this new NOFO. This NOFO will utilize the R21/R33 activity code.

How to apply

0 of 8 done · progress saved in this browser

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.242

Historical data · not a prediction
FY24$1.72B
FY25$1.73B
FY26$99.2M est.
Source: SAM.gov Assistance Listing 93.242. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Division of AIDS Research
NIMH.DAR.inquiries@nih.gov
Please contact via email.

Quick answers

Is this opportunity open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around August 17, 2026. Forecast details and dates can change.

Who is eligible to apply for this opportunity?

The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through this opportunity?

Per the notice, total estimated program funding is $2,000,000 and the agency expects to make about 4 awards.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-MH-27-110), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.